The lucrative 'Project Blueprint' franchise is facing a massive internal shakeup after the biohacker’s white blood cells reportedly walked away from the negotiating table.
The rollout for Bryan Johnson’s highly anticipated immortality campaign has hit a massive internal snag. The tech centimillionaire and self-styled medical IP sat down with TMZ’s Charlie Neff this week to do aggressive damage control, confirming industry murmurs that his biological infrastructure has officially been put in turnaround following an incurable autoimmune dispute.
Sources close to the production indicate that despite a rigid 111-pill daily call sheet and heavy investment in teenage blood-plasma attachments, Johnson’s own white blood cells have gone entirely rogue. The antibodies reportedly bypassed his management team altogether, launching an unscripted attack on his internal organs and refusing to renew their overall deal with his central nervous system.
You greenlight a two-million-dollar immortality tentpole, get the premium blood-boy deliverables locked in, and suddenly the host's own thyroid decides it wants a rewrite.
Insiders say Johnson’s reps are already working the trades to spin the incurable disease as a gritty, grounded reboot of the Project Blueprint franchise. While early tracking numbers for his bone density remain solid in international markets, the internal biological friction has forced the Venice-based outfit to quietly scale back his Q4 press tour.
If the rogue T-cells refuse to play ball before awards season, industry analysts warn the entire physical vessel may be shelved as a total write-off.